Qingfeng Pharmaceutical's Class 1 innovative drug GP681 tablets made significant progress
2020-09-17
On August 25, 2020, our clinical research team held a GP681 clinical study kick-off meeting in Shanghai Xuhui District Central Hospital, marking that our innovative drug GP681 has officially entered the phase I clinical study.
Next：This is the last one
Prev：This is the first article